Tranexamic acid is a derivative of the amino acid lysine that has historically been used to treat bleeding disorders (R). In 1988, it was discovered to also suppress skin pigmentation induced by exposure to UV radiation (R), leading to its emergence as a treatment for hyperpigmentation (R).
Tranexamic acid has been observed to be relatively stable when incorporated in liposome formulations, with >90% remaining after up to 2 months of storage when kept at temperatures no higher than 30°C (R).
Tranexamic acid is highly hydrophilic, making its penetration of the hydrophobic skin barrier challenging (R). However, the use of penetration enhancers (R), novel formulations (R, R, R), microneedling (R) and laser treatment (R, R) have been shown to improve its delivery into the skin.
Outcome | Grade | Effect | Studies | |||||||
---|---|---|---|---|---|---|---|---|---|---|
Hyperpigmentation |
A
|
|
|
|||||||
Skin Brightness |
C
|
|
|
|||||||
Skin Redness |
C
|
|
|
|||||||
Melasma |
E
|
|
|
Outcome | Grade | Effect | Studies | |||||||
---|---|---|---|---|---|---|---|---|---|---|
Endothelin-1 |
C
|
|
|
|||||||
Stem Cell Factor |
C
|
|
|
|||||||
Tyrosinase |
D
|
|
||||||||
Melanin |
E
|
|
|
|||||||
CD-31 |
E
|
|
|